Compare IIIN & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIIN | CTNM |
|---|---|---|
| Founded | 1953 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.9M | 550.7M |
| IPO Year | 1994 | 2024 |
| Metric | IIIN | CTNM |
|---|---|---|
| Price | $30.58 | $17.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 128.7K | ★ 534.3K |
| Earning Date | 04-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | ★ 112.12 | 0.46 |
| EPS | ★ 1.12 | N/A |
| Revenue | ★ $647,706,000.00 | N/A |
| Revenue This Year | $14.20 | N/A |
| Revenue Next Year | $6.82 | N/A |
| P/E Ratio | $27.09 | ★ N/A |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $24.35 | $8.60 |
| 52 Week High | $39.91 | $17.51 |
| Indicator | IIIN | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 62.30 |
| Support Level | $30.49 | $13.65 |
| Resistance Level | $31.04 | N/A |
| Average True Range (ATR) | 0.72 | 0.86 |
| MACD | -0.14 | 0.07 |
| Stochastic Oscillator | 37.01 | 96.43 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.